SCHEMBL3664615

SCHEMBL3664615

CCN(Cc1c(N(C=O)CCOc2ccc(C(=O)Nc3ccccc3N)cc2)oc2ccccc12)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 13/20 0.42
HDAC2 Q92769 8/20 0.42
HDAC3 O15379 7/20 0.42
NCOR2 Q9Y618 3/20 0.42
MCHR1 Q99705 1/20 0.41
HDAC10 Q969S8 4/20 0.40
HDAC8 Q9BY41 4/20 0.40
HDAC6 Q9UBN7 4/20 0.40
HDAC4 P56524 3/20 0.40
HDAC7 Q8WUI4 3/20 0.40
HDAC11 Q96DB2 3/20 0.40
HDAC9 Q9UKV0 3/20 0.40
HDAC5 Q9UQL6 3/20 0.40
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK10 P53779 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663340 0.91 HDAC2 (0.44) HDAC1HDAC2HDAC3NCOR2MCHR1
SCHEMBL3664760 0.90 HDAC1 (0.49) HDAC1HDAC2HDAC3NCOR2MCHR1
SCHEMBL3662811 0.89 HDAC2 (0.46) HDAC1HDAC2HDAC3NCOR2MCHR1
SCHEMBL3663556 0.87 HDAC2 (0.45) HDAC1HDAC2HDAC3MCHR1HDAC10
SCHEMBL3664208 0.87 HDAC1 (0.46) HDAC1HDAC2HDAC3MCHR1HDAC10
SCHEMBL3660289 0.87 HDAC2 (0.46) HDAC1HDAC2HDAC3MCHR1HDAC10
SCHEMBL3663336 0.86 HDAC1 (0.44) HDAC1HDAC2HDAC3HDAC10HDAC8
SCHEMBL3663699 0.85 HDAC2 (0.43) HDAC1HDAC2HDAC3NCOR2MCHR1
SCHEMBL3664788 0.85 HDAC1 (0.47) HDAC1HDAC2HDAC3NCOR2HDAC10
SCHEMBL3664384 0.85 HDAC2 (0.47) HDAC1HDAC2HDAC3MCHR1HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2010-11-18 US claimed
EP-2220066-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS Gilead Colorado, Inc. (US) 2010-08-25 EP claimed
WO-2009079391-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2009-06-25 WO claimed
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2010-11-18 US disclosed
EP-2220066-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS Gilead Colorado, Inc. (US) 2010-08-25 EP disclosed
WO-2009079391-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS GILEAD COLORADO, INC. (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292320-A1 BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC7, HDAC5 HDAC1 1/4885HDAC2 4/4885HDAC3 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.